Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116418 | 0.85 | ADRB1 (0.54) | ADRB1HTR2AHTR2BSIGMAR1HTR1A | |
| SCHEMBL3411478 | 0.85 | ADRB1 (0.70) | ADRB1HTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL2115763 | 0.85 | ADRB1 (0.70) | ADRB1HTR2AHTR2BSIGMAR1MEN1 | |
| SCHEMBL2114668 | 0.82 | ADRB1 (0.70) | ADRB1HTR2AHTR2BSIGMAR1HTR1A | |
| SCHEMBL2116100 | 0.82 | ADRB1 (0.50) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL904492 | 0.82 | ADRB1 (0.55) | ADRB1HTR2AHTR2BSIGMAR1 | |
| SCHEMBL2114232 | 0.81 | ADRB1 (0.49) | ADRB1HTR2AHTR2BSIGMAR1MAPT | |
| SCHEMBL2113715 | 0.78 | ADRB1 (0.64) | ADRB1HTR2AHTR2BSIGMAR1HTR1A | |
| SCHEMBL2296644 | 0.78 | MEN1 (0.56) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL7760522 | 0.77 | SIRT6 (0.54) | KMT2APOLBALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815852-B2 | Carbamoyloxy arylalkan arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-26 | — | — | US | claimed |
| CN-101679400-B | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | SK HOLDINGS CO LTD | 2013-04-17 | — | — | CN | claimed |
| US-8815852-B2 | Carbamoyloxy arylalkan arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8815852-B2 | Carbamoyloxy arylalkan arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| US-8815852-B2 | Carbamoyloxy arylalkan arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| EP-2150550-B1 | NOVEL CARBAMOYLOXY ARYL ALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120095007-A2 | CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE ANALGESICS | SK HOLDINGS CO. LTD. (KR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095007-A2 | CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE ANALGESICS | OPRL1, OPRD1, TRPV1 | ADRB1 315/4885HTR2A 31/4885HTR2B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.